Ken H Young, PhD

Editorial Board Member

Department of Hematopathology
The University of Texas MD Anderson Cancer Center, USA

Contact Ken H Young, PhD

Department / University Information


Ken H. Young is a Professor at The University of Texas MD Anderson Cancer Center in the Department of Hematopathology. Young completed his MD at Zhejiang University School of Medicine, China in 1984. Dr. Ken primary study of genomic alterations is on TP53 tumor suppressor pathway. His secondary focus is on Myc oncogene. Weblink to MD Anderson SciVal research profile and PubMed list of publication is attached. Ken research team performs several types of hematologic malignancies, with special emphasis on pathogenesis of malignant lymphomas, especially diffuse large B-cell lymphoma (DLBCL). DLBCL is an aggressive B-cell lymphoma which brings together the worst characteristics of both high-grade features and aggressive biology. The disease is incurable in nearly 40% patients. Ken has published over 134 articles in different journals. Dr. Ken has worked as committee member at American Board of Pathology, Anatomic and Clinical Pathology and American Board of Hematology. Currently, Dr. Ken is Vice-Chair for IRG Pilot Grant Review Committee at The University of Texas MD Anderson Cancer Center, Houston.

Research Interest

Ken H Young goal is to explore and identify genetic and non-genetic biomarkers, including p53, Myc, pTEN, Mdm2, Arf, Bcl-2, Bcl-6 genes, alone or in combination with other abnormalities in DLBCL, that predict cancer prognosis and susceptibility. The central hypothesis is based on the concept that tumor suppressor gene or oncogene is often deregulated in carcinogenesis. The presence of mutations, deletion, insertion and translocation is correlated with a poor response to treatment, rapid disease progression, and short survival in human cancer.